Our top pick for
Tricida, Inc is a drug manufacturers—specialty & generic business based in the US. Tricida shares (TCDA) are listed on the NASDAQ and all prices are listed in US Dollars. Tricida employs 157 staff and has a market cap (total outstanding shares value) of USD$320.7 million.
Since the stock market crash in March caused by coronavirus, Tricida's share price has had significant negative movement.
Its last market close was USD$6.41, which is 82.64% down on its pre-crash value of USD$36.93 and 181.20% down on the lowest point reached during the March crash when the shares fell as low as USD$18.025.
If you had bought USD$1,000 worth of Tricida shares at the start of February 2020, those shares would have been worth USD$572.23 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$172.04.
|Latest market close||USD$6.41|
|52-week range||USD$4.1 - USD$44.3|
|50-day moving average||USD$7.9804|
|200-day moving average||USD$16.7907|
|Wall St. target price||USD$13|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.006|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-13)||-0.77%|
|1 month (2020-10-21)||-27.49%|
|3 months (2020-08-21)||-51.59%|
|6 months (2020-05-21)||-76.11%|
|1 year (2019-11-21)||-84.30%|
|2 years (2018-11-21)||-78.68%|
|3 years (2017-11-20)||N/A|
|5 years (2015-11-20)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-41.75%|
|Return on equity TTM||-113.52%|
|Market capitalisation||USD$320.7 million|
TTM: trailing 12 months
There are currently 3.5 million Tricida shares held short by investors – that's known as Tricida's "short interest". This figure is 28.1% up from 2.7 million last month.
There are a few different ways that this level of interest in shorting Tricida shares can be evaluated.
Tricida's "short interest ratio" (SIR) is the quantity of Tricida shares currently shorted divided by the average quantity of Tricida shares traded daily (recently around 1.6 million). Tricida's SIR currently stands at 2.2. In other words for every 100,000 Tricida shares traded daily on the market, roughly 2200 shares are currently held short.
However Tricida's short interest can also be evaluated against the total number of Tricida shares, or, against the total number of tradable Tricida shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Tricida's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Tricida shares in existence, roughly 70 shares are currently held short) or 0.2052% of the tradable shares (for every 100,000 tradable Tricida shares, roughly 205 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Tricida.
Find out more about how you can short Tricida stock.
We're not expecting Tricida to pay a dividend over the next 12 months.
Tricida's shares were split on a 1:3 basis on 15 June 2018. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Tricida shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Tricida shares which in turn could have impacted Tricida's share price.
Over the last 12 months, Tricida's shares have ranged in value from as little as $4.1 up to $44.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tricida's is 1.1947. This would suggest that Tricida's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Tricida, Inc., a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). The company has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis. Tricida, Inc. was founded in 2013 and is headquartered in South San Francisco, California.
Steps to owning and managing CBAY, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHAP, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRS, with 24-hour and historical pricing before you buy.
Steps to owning and managing AXLA, with 24-hour and historical pricing before you buy.
Steps to owning and managing ALOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMPE, with 24-hour and historical pricing before you buy.
Steps to owning and managing UHAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ALIM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ACU, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.